Symbols

FLNA

Filana Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FLNA

Filana Therapeutics, Inc.

A clinical-stage biotechnology company headquartered in Austin, Texas

Industry

Pharmaceutical

Established Date

Listing Date

07/14/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.filanatx.com

Security Type

Common stock

Office address

6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731

Business

Introduction

Filana Therapeutics, Inc., was incorporated in Delaware in May 1998. The company is a clinical-stage biotechnology company headquartered in Austin, Texas. The company is committed to developing transformative drugs to improve the lives of patients with central nervous system diseases, focusing on diseases related to filament A disorders or overexpression, such as tuberous sclerosis-related epilepsy. At the heart of its scientific approach lies in regulating the activity of this key protein in the brain. The company's main therapeutic drug under development, simufilam, is an oral proprietary small molecule drug originally developed for Alzheimer's disease. After the Alzheimer's disease program was completely terminated by the middle of 2025, the company refocused its efforts. Simufilam is currently being studied for the treatment of tuberous sclerosis-related epilepsy, targeting filament protein A, a novel mechanism of action independent of the traditional mTOR pathway. Preclinical studies suggest that this potentially pioneering filament A modulator may improve neuronal overgrowth and malformations that cause seizures in patients with tuberous sclerosis. The Company will continue to explore other potential indications where simufilam may have efficacy in preclinical trials, including central nervous system related and other areas.

Company Financials

EPS

FLNA has released its 2025 Q4 earnings. EPS was reported at -0.26, versus the expected -0.27, beating expectations. The chart below visualizes how FLNA has performed over recent quarters, highlighting trends in earnings surprises.